Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | APAF1 | O14727 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764961 | 0.83 | ADRB1 (0.45) | ALDH1A1HPGDKDM4EAPAF1POLB | |
| SCHEMBL6762612 | 0.80 | CFD (0.49) | CFD | |
| SCHEMBL6762841 | 0.80 | ZAP70 (0.42) | ALDH1A1HPGDKDM4EAPAF1POLB | |
| SCHEMBL6766787 | 0.78 | NPY1R (0.39) | — | |
| SCHEMBL6771779 | 0.78 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4EMAPTLMNA | |
| SCHEMBL6886512 | 0.78 | CFD (0.47) | ALDH1A1HPGDKDM4EHTR2ALMNA | |
| SCHEMBL7250884 | 0.78 | CFD (0.39) | ALDH1A1HPGDKDM4EMAPTCFD | |
| SCHEMBL6765436 | 0.78 | ADRA1A (0.47) | CFD | |
| SCHEMBL29429638 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HPGDKDM4EAPAF1POLB | |
| SCHEMBL27387450 | 0.77 | CFD (0.44) | ALDH1A1KDM4EMAPTCFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | ALDH1A1 557/4885HPGD 533/4885KDM4E 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.